研究单位：[1]ImmuneOnco Biopharmaceuticals (Shanghai) Inc.[2]Institute of Hematology & Blood Diseases Hospital[3]Beijing gobroad boren hospital,Beijing,China[4]Peking university third hospital,Beijing,China[5]Xuanwu Hospital, Capital Medical University,Beijing,China[6]Chongqing university cancer hospital,Chongqing,China[7]Second Affliated Hospital of Army Medical University,Chongqing,China[8]Fujian medical university union hospital,Fuzhou,China[9]Ganzhou People's Hospital,Ganzhou,China[10]Guangdong provincial people hospital,Guangzhou,China[11]Nanfang Hospital, Southern Medical University,Guangzhou,China[12]Zhujiang Hospital, Southern Medical University/The Second School of Clinical Medicine, Southern Medical University,Guangzhou,China[13]The first affiliated hospital zhejiang university school of medicine,Hangzhou,China[14]The first affiliated hospital of nanchang University,Nanchang,China[15]Ruijin Hospital, Shanghai Jiaotong University School of Medicine,Shanghai,China[16]Shanghai sixth's hospital,Shanghai,China[17]Tongren hospital shanghai jiaotong university school of medicine,Shanghai,China[18]Shengjing Hospital Affiliated to China Medical University,Shenyang,China[19]The First Hospital of China Medical University,Shenyang,China[20]Tianjin Blood Disease Hospital,Tianjin,China[21]Union Hospital Tongji Medical College Huazhong University of Science and Technology,Wuhan,China[22]The affiliated hospital of Xuzhou medical university,Xuzhou,China[23]Henan Cancer Hospital,Zhengzhou,China[24]The first affiliated hospital of Zhengzhou University,Zhengzhou,China
研究目的：
This trial is an open-lable , multi-center, Phase 1/Phase 2 study that will evaluate the safety, tolerability, Pharmacokinetics, Pharmacodynamics and and immunogenicity of IMM01 combined with Azacitidine in patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS).
